The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (3), Page 6324-6330

Lower Respiratory Tract Infection in Pediatrics, Treatment Approaches: Review Article

Mohammed Hundur Alasmari, Abdulaziz Abdullah Alhazmi, Abdullah Salem Al Haider, Yaqoub Mubarak Ali Alhamami, Nasser Naji Mohsen Al harthi, Mana Ali Mueidh Al hajlan

Medical school, Najran University, Najran, KSA

Abstract:
This article outlines the etiology and epidemiology of childhood acute lower respiratory tract infections (ALRI), preventative measures, and management of the most common and important cause of ALRI, pneumonia.
Method: We conducted a review to determine the proper treatment of Lower respiratory tract infection in pediatrics. In May 2018 we searched PubMed, Medline, and EMBASE databases
Conclusion: Viral lower respiratory system infections in newborns and children are important clinical and socioeconomic problems worldwide. Viral lower respiratory system infections are mild and self-restricting in many cases. Specific patient groups are at risk of a severe program of illness, although formerly healthy infants with a viral lower respiratory tract infection may additionally develop extreme illness.
Keywords: Respiratory Tract Infection, Pediatrics, pneumonia, Treatment Approaches.

Introduction:
According to world health organization (WHO) estimates, even more than 150 million episodes of community-acquired pneumonia and 2 million pneumonia-related deaths took place in the year 2008 amongst children under five years of age in creating countries. Of all pneumonia instances, 7-13% were sever enough to be life-threatening and necessary hospitalization [1] . To decrease the morbidity and mortality caused by pneumonia in youngsters below 5 years in resource-poor countries the WHO has developed a basic situation-management approach of acute respiratory infection (ARI) in the 1980s with early diagnosis of pneumonia and empirical antibacterial treatment [2]. The basis for the case-management program was that nearly all ARI-related death was caused by bacterial pneumonia. According to the protocol, pneumonia can be differentiated from other respiratory diseases by trained paramedical healthcare providers using basic medical signs in primary health facilities [3]. The WHO integrated the ARI instance- management standards right into the medical protocols of "The Integrated Management of Childhood Illnesses (IMCI)" and the program had been taken on by many establishing nations [4]. These guidelines consisted of referrals for the instance- management of acute childhood illnesses and guidance when referral to greater levels of care is needed. They specify appropriate anti-bacterial therapy and precautionary treatments against the leading reasons for youth mortality [5]. This strategy has been effective in reducing ARI- related mortality in kids below 5 years in developing nations [6]. Over time, to increase the specificity of the guidelines, the programs have advanced [7]. Our goals in this narrative review are: to define and diagnose pneumonia and its subtypes based on the WHO standards, to define the most ideal antibacterial agent for different settings of diseases "simple versus sever and really sever pneumonia", to diagnose and discuss one of the most suitable approaches to cases with treatment failing, and lastly to define patients that have benefited from other treatments.
This article outlines the etiology and epidemiology of childhood ALRIs, preventative measures, and management of the most common and important cause of ALRI, pneumonia.

Methodology:
We conducted a review to determine the proper treatment of Lower respiratory tract infection in pediatrics. In May 2018 we searched PubMed, Medline, and EMBASE databases using the search terms: LRTI in pediatrics, including acute lower respiratory illness and bronchiolitis. Search results were restricted to English language with human subjects.

Received: 16/7/2018
Accepted: 26/7/2018

Discussion:

- **Epidemiology of Acute Lower Respiratory Tract Infections**

Acute respiratory infections are the most typical infection in children and include a wide range of diseases from colds, pharyngitis and influenza, to lower respiratory system infections. Clinically, acute lower respiratory tract infections (ALRTI) can be split right into pneumonias and bronchiolitis [8]. Distinctions in between these 2 conditions could be specifically difficult in kids [9]. Although the regularity of ARI is comparable in both created and developing countries [10], morbidity and death due to ARI is 10-15 times greater in developing nations [11]. The annual incidence of pneumonia in kids younger compared to five years in establishing nations is not only more typical: 7-40 versus 2-4 cases/100 kids specifically, but likewise is a lot more extreme contrasted to exactly what occurs in industrialized countries [12]. In 2010, greater than 11.9 million episodes of serious pneumonia, 3 million cases of very serious pneumonia and 1.4 million deaths occurred in young children worldwide, causing a considerable worry on care systems [12]. In spite of the inadequacy of research into the epidemiological root causes of pneumonia, certain danger factors have been determined. Younger age, reduced birth weight, congestion and big family members size, poor nutrition, and early childhood respiratory damages due to indoor air pollution were the major considerable elements for advancement of pneumonia [13]. Likewise, threat aspects related to enhanced death in situations with ALRTI were investigated and the age much less than one year, failure to feed, extreme malnutrition and those with loose stools during an acute episode were found to be at greater danger of deaths [14].

- **Etiology of ALRTI**

Several microorganisms mainly viruses and bacteria cause ALRTI in infants and youngsters. Developing a microbial diagnosis for pneumonia is difficult. Identification or prediction of the most likely organism creating ALRTI is one of the most important action in choosing proper therapy. The limited available data showed that the respiratory viruses consisting of respiratory syncytial virus (RSV), influenza infection (FLU) and bacteria such as streptococcus pneumonia (Spn) and homophiles influenza kind B (Hib) are one of the most common microbial agents triggering pneumonia in children. The relative distribution of these pathogens differed with condition severity with Spn and Hib being one of the most essential microbial agents in the events with severe illness [15]. In a hospital-based study in Pakistan, RSV was identified in 33% with Spn and Hib in 9.9% and 4.6%, respectively of hospitalized patients with WHO specified severe and extremely extreme pneumonia [16]. In a research study in India, viruses were identified in 49% of patients with ALRTI and RSV was the commonest representative [17]. Throughout a one year research study carried out in Iran, one or more breathing infections were determined from 54% of hospitalized patients with ALRTI Parainfluenza viruses in 15.8% and RSV vn 12.9% were one of the most usual representatives [18]. In another study which included 14 Asian countries isolates from lung aspirate of hospitalized children were assessed, and Spn was discovered as the commonest isolate followed by Hib. Combined viral and bacterial infections occurred regularly [19].

- **Pneumonia definition and medical diagnosis of ALRTI**

The definitions of pneumonia vary widely. Acute pneumonia is generally specified as an infection of the alveoli and interstitial tissues of the lung that is noted by signs of acute infection such as high temperature, coughing and dyspnea, and is typically related to unusual auscultatory findings (eg; rales, modified breath sounds) or the presence of infiltrate on chest imaging. The WHO has defined pneumonia entirely on the basis of clinical findings gotten by visual inspection and timing of respiratory rate. Definitions are a particular issue in small babies, since pneumonia and bronchiolitis are both usual, and the features of these two diseases typically overlap [9,10]. The WHO identifies pneumonia as an acute episode with coughing or difficult breathing gone along with by rapid breathing (tachypnea). According to the protocol for a child younger compared to 5 years, easy (non-severe) pneumonia is indicated by a respiratory rate of $\geq$ 50 breath each minute in a child study was conducted to examine the reliability of age appropriate respiratory rate and various other clinical signs and symptoms in the medical diagnosis of pneumonia in children 80% yet were observed only in a tiny proportion of patients [20].

- **Treatment (management) of ALRTI**

Early diagnosis and timely establishment of empiric anti-bacterial treatment is the mainstay of the WHO/IMCI/ARI case-management standards to reduce pneumonia related death in creating countries. According to protocol any kind of patient with severe and/or extremely serious pneumonia needs medical facility admission for parenteral drugs, whereas those with basic pneumonia (situations only with tachypnea) might be treated at residence with an oral first-- line anti-bacterial representative. The guidelines additionally suggested that all infants younger compared to 2 month of age with pneumonia must be hospitalized as a serious situation and treated with parenteral antibiotics [3]. The first-line antibiotics must be guided primarily at the 2 treatable pathogens. However, the first-line anti-bacterial representatives ought to be efficient, reliable, extensively available and affordable in resource-poor nations. For the empiric treatment of non- extreme pneumonia at a first-- level wellness center, technical upgrade of the WHO/IMCI guidelines released in 2005 suggested oral Amoxycillin (Amx) (50 mg/kg/day in two separated dose) or Co-trimoxazole (Co-tr) (8 mg/kg/day of trimethoprim in 2 divided dose) as the very first-line treatment because of their reduced cost and wide-spectrum coverage [21]. A method that targets the two primary bacterial agents, Snp and Hib, has been repetitively revealed to be effective in reducing pneumonia death with studies and medical experience over the previous 2 years [13].

Using the IMCI standards to treat pneumonia in establishing regions has assisted to reduce pneumonia-related death significantly [6]. Nevertheless, nearly 20-30% of instances fulfilling the WHO standards for nonsevere pneumonia get unnecessary antibiotics for possible non-severe lower respiratory infections [22]. Research studies from Asia reported that a big proportion of antibacterial therapy failing for pneumonia occurred in children with wheeze that were misclassified as pneumonia [7]. In order to attend to the concern of pneumonia over-categorization and reasonable use of anti-biotics in youngsters with wheeze the IMCI guidelines and other studies [21].

Suggested providing 2 cycles of fast acting inhaled bronchodilator at 15 min intervals to patients with a diagnosis of pneumonia however an audible wheeze prior to continuing for antibiotic therapy. If the patient's condition improved and east breathing and chest retraction solved after inhaled medicine they are reclassified as "no pneumonia" and discharged with a breathed in bronchodilator. Nevertheless, a lot of babies with wheeze have viral bronchiolitis and do not react to bronchodilators [23]. As a result of renovation in socio-economic problems and vaccination of kids versus Hib in many creating countries, raised accessibility of more recent anti-biotics and the introduction of antibacterial resistance the WHO just recently embarked on a professional review of the IMCI standards for area- acquired pneumonia case- management [24]. These upgraded recommendations currently identify Amx as the favored initially-line representative. For the treatment of situations with extreme and very severe pneumonia in the healthcare facility setup, the 3rd cephalosporins, e.g. ceftriaxone, were advised as one of the most ideal antibiotic versus resistant Spn and Hib. It would certainly serve for a second line representatives to be much more expensive than first-- line medicines. Nonetheless, the possibility of overuse in establishing countries, their use in the out-patient facilities are not recommended. Although, most oral second- and 3rd generation cephalosporins have improved protection against beta-lactamase creating Hib, however are not as energetic as high-dose Coamx/Amx against Spn, for that reason, they are not advised as a choice. Beta-lactam antibiotics do not offer protection versus atypical agents causing pneumonia such as Mycoplasma pneumonia and chlamydophila pneumonia. Macrolides and azalides (erythromycin, clarithromycin, azithromycin) are priced moderately, yet are fairly inactive against Hib and additionally, there is an increasing resistance versus Spn. One of the most essential role of macrolides and azalides is their activity against Mycoplasma and Chlamydia pneumonia. Therefore, whens it comes to first-line therapy failures in children $\geq$ 3 years, or as the first-line antibiotic in cases older than 5 years these drug are suggested [24]. Many researches worldwide [25] suggested that between 17% and 90% of children with ARIs are getting antibiotics, which are inappropriate most of situations [25].The overuse of anti-bacterial agents could bring about development of bacterial resistance, adverse

effects, and financial cost to both the patient and the community. To rationalize antibiotic prescription, adherence to IMCI/WHO basic ARI case-management guidelines is advised.

- **Treatment failure**

In instances with straight forward pneumonia, details empiric antibacterial treatment should cause reduction of respiratory rates and renovation in the general problems within 48 hrs. of therapy [26]. Development of chest-wall in- drawing or event of threat indications at any moment during treatment are specified as therapy failing. In this scenario, for more assessment and inpatient care instant reference is required [21,24]. If within 72 hours of treatment, the patient general conditions dosage not deteriorate and consistent tachypnea is still observed (respiratory rate vs not decreased by ≥ 5 breaths/minute), prior to reference and/or changing antibiotic, a short yet systematic analysis by the primary wellness care provider is needed to assess feasible root causes of unresponsiveness to treatment (Figure 1) [24]. If the evaluation suggests incorrect use the antibiotic, and presence of wheezing, HIV, and TB are unlikely and referral is not called for, a second-line anti-bacterial agent with broader coverage is advised. In this circumstance, high dosage Amoxycillin (80- 100 mg/kg/day) with Clavulanic acid (coAmx) for 5 days, or if patient is older than 3 years an affordable macrolide/azalide ought to be added to the existing Amx. If the initial therapy was with Co-tr altering to the basic dose of Amx for 5 day is suggested [21,24].

For instances with severe and/or very extreme disease In-hospital care management, the second- line anti-bacterial agents ought to make certain protection of resistant organisms and cover a broader array of organisms that would not be treated with typical first-line representatives. Of those, expense of treatment was thought to be the next essential element. The standards advised antibiotics consisted of parenteral intravenous chloramphenicol (100mg/ kg/day divided every 6 hrs.) or benzyl-penicillin (200000 unit/kg/day divided every 6 hours) combined with gentamicin (7.5 mg/kg/day split every 12 hrs.) [21]. If a youngster meets standards for recommendation however this is difficult, the kid needs to be treated with the same antibiotics. Along with administration, and bronchodilators antibacterial treatment, the WHO guidelines include intravenous liquid therapy, O2 as scientifically shown based on seriousness of the disease [21].



Figure 1. Algorithm of systematic management in children 2 to 59 months of age with non-severe pneumonia and persistent tachypnea 48-72 hours after initiation of antibacterial therapy [25].

- **Preventative measures for respiratory illnesses**

In addressing avoidance of acute respiratory disease, the indisputable importance of the social factors of health is recognized but cannot be sufficiently addressed here. Health is linked with every element of life: education and learning, human rights, social justice, the environment, economy, and work. Redressing health equity with action on the social determinants of health has been recently supported by the World Health Organization (WHO) [27]. A Canadian study on pneumonia and influenza determined that reduced education, being Aboriginal, behavior elements (day-to-day smoking cigarettes and heavy alcohol consumption), ecological variables (passive smoking, inadequate housing, temperature), and health care variables (influenza vaccination) were all considerably associated with raised rates in different age- and gender-specific designs [28]. Particular (instead of socioeconomic-educational) primary prevention actions for respiratory illness are only briefly discussed right here, and broadly categorized into (1) promoting normal lung advancement and (2) eliminating risk elements for advancement of respiratory illness. Both share common treatment features provided here. These factors have restricted randomized controlled trial (RCT) proof, and it is extremely unlikely such studies will certainly ever before be ethically performed. However, it is suggested that the aspects detailed right here are implemented for population wellness [29].

Table 1. Prevention strategies in children [30]:

• Avoidance of in utero and environmental tobacco smoke exposure. Tobacco smoke exposure is a major issue affecting Indigenous children.
• Prevention of low birth weight infants and prematurity. Low birth weight babies are at greater risk of poor health and respiratory illnesses. Contributors to low birth weight include socioeconomic disadvantage, size of parents, age of the mother, number of babies previously born, mother's nutritional status, smoking and alcohol intake, and illness during pregnancy.
• Promotion of breast feeding (preferably exclusive for at least 4 months). Breast feeding has been recurrently shown to be a protective factor for acute respiratory infections and other illnesses.
• Improvement in the living environment, particularly running water, overcrowding, and ventilation.
• Appropriate and early treatment of respiratory infections including adequate follow-up, and detection of treatment failure and recurrent infections.
• Avoidance of biomass combustion (particularly indoor cooking fires) and other air pollutants that contribute to acute respiratory infections.
• Promotion of improved nutrition and postnatal growth.
• Complete and timely immunizations, particularly that of yearly influenza vaccinations, for which uptake is currently poor despite being recommended in national guidelines in North America and Australia for children from 6 months of age.
• Improved parenting. Parenting moderates the effects of poverty and underclass condition. Although no information exist on the effect of nurse house visiting programs on infectious conditions, parenting programs has been shown to improve birth weight, bust feeding, and hospitalization. Preliminary research studies in AI/AN populations making use of paraprofessionals described efficacy in improving mother's knowledge and baby behavior results, therefore recommending parenting interventions could be helpful in such areas.

Conclusion:

Viral lower respiratory system infections in newborns and children are an important clinical and socioeconomic problem worldwide. Viral lower respiratory system infections are mild and self-restricting in many cases. Specific patient groups are at risk of a severe program of illness, although formerly healthy infants with a viral lower respiratory tract infection may additionally develop extreme illness.

The IMCI/ARI case management has been effective in decreasing pneumonia relevant mortality in youngsters< 5 years old in developing countries. Nevertheless, this protocol led to overuse of antibiotics in some cases with ALRTI who were misclassified as pneumonia. To reduce antibiotic over prescription, guidelines recommended providing 2 cycles of fast acting bronchodilator inhaler to patients categorized as pneumonia and audible wheeze. The protocols had developed overtime. In this reading Amoxycillin was recommended as the first-line treatment with simple pneumonia and third-generation cephalosporin for those with severe/very severe pneumonia in the health center setups. To rationalize antibiotic prescription, adherence to WHO standard case-management protocols is recommended. Additionally, to enhance the identification of true pneumonia cases in children that met the WHO criteria for diagnosing pneumonia cases appropriate usage of various other clinical findings such as rales, wheeze, laboratory data such as white blood cell counts and polymorphonuclear cells, erythrocyte sedimentation rate and chest imaging are recommended.

Reference:

1. **Rudan I1, Boschi-Pinto C, Biloglav Z *et al.* (2008):** Epidemiology and etiology of childhood pneumonia. Bull World Health Organ., 86(5):408-16.
2. **World Health Organization (1981):** Clinical management of acute respiratory infections in children: a WHO memorandum. Bull World Health Organ., 59(5):707-16.
3. **Shann F, Hart K, Thomas D (1984):** Acute lower respiratory tract infections in children: possible criteria for selection of patients for antibiotic therapy and hospital admission. Bull World Health Organ., 62(5): 749-53.
4. **Shann F (1995):** The management of pneumonia in children in developing countries. Clin Infect Dis., 21(3): 218-25.
5. **Shah D, Sachdev HP (1999):** Evaluation of the WHO/UNICEF algorithm for integrated management of childhood illness between the age of two months to five years. Indian Pediatr., 36(8):767-77.
6. **Sazawal S, Black RE (2003)**: Effect of pneumonia case management on mortality in neonates, infants, and preschool children: a metaanalysis of community-based trials. Pneumonia Case Management Trials Group. Lancet Infect Dis., 3(9): 547-56.
7. **Sachdev HP, Vasanthi B, Satyanarayana L *et al.* (1994):** Simple predictors to differentiate acute asthma from ARI in children: implications for refining case management in the ARI Control Programme. Indian Pediatr., 31(10):1251- 9.
8. **Glezen P, Denny FW (1973):** Epidemiology of acute lower respiratory disease in children. N Engl J Med., 288(10):498-505.
9. **Don M, Valent F, Korppi M *et al.* (2009):** Differentiation of bacterial and viral community-acquired pneumonia in children. Pediatr Int., 51(1): 91-6.
10. **Pavia AT (2011):** Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis., 52(4):284-9.
11. **Selwyn BJ (1990):** The epidemiology of acute respiratory tract infection in young children: comparison of findings from several developing countries. Coordinated Data Group of BOSTID Researchers. Rev Infect Dis., 12 (8): 870-88.
12. **Nair H, Simões EA, Rudan I *et al.* (2013):** Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet, 381(9875):1380-90.
13. **Singh V (2005):**The burden of pneumonia in children: an Asian perspective. Paediatr Respir Rev., 6(2): 88-93.
14. **Sehgal V, Sethi GR, Sachdev HP *et al.* (1997):** Predictors of mortality in subjects hospitalized with acute lower respiratory tract infections. Indian Pediatr., 34(3): 213-9.
15. **Ayieko P, English M (2007):** Case management of childhood pneumonia

in developing countries. Pediatr Infect Dis J., 26(5): 432-40.

16. **Ghafoor A, Nomani NK, Ishaq Z *et al.* (1990):** Diagnoses of acute lower respiratory tract infections in children in Rawalpindi and Islamabad, Pakistan. Rev Infect Dis., 12 (8): 907-14.
17. **John TJ, Cherian T, Steinhoff MC *et al.* (1991):** Etiology of acute respiratory infections in children in tropical southern India Rev Infect Dis., 13(6): 463-9.
18. **Saffar MJ, Naghshvar F, Alaee E (2002):** Role of respiratory syncytial and Influenza viruses in acute lower respiratory tract infections in mazandaranian children in 2002. J Mazandaran Univ Med Sci., 12(37): 20–9.
19. **Berman S (1991):** Epidemiology of acute respiratory infections in children of developing countries. Rev Infect Dis., 13(6): 454-62.
20. **Dai Y1, Foy HM, Zhu Z *et al.* (1995):** Respiratory rate and signs in roentgenographically confirmed pneumonia among children in China. Pediatr Infect Dis J., 14(1): 48-50.
21. **WHO (2005):** Technical update of the guidelines on the integrated management. Geneva. **http://www.who.int/maternal_child_adolescent/topics/child/imci/en/**
22. **World Health Organization (2003):** Consultative meeting to review evidence and research priorities in the management of acute respiratory infections. WHO/ ARI/ 04.2 Geneva, WHO, Meeting Report. https://doi.org/10.1016/S1473-3099(09)70044-1
23. **Hazir T, Qazi S, Nisar YB *et al.* (2004):** Assessment and management of children aged 1-59 months presenting with wheeze, fast breathing, and/or lower chest indrawing; results of a multicentre descriptive study in Pakistan. Arch Dis Child., 89(11): 1049-54.
24. **Grant GB1, Campbell H, Dowell SF *et al.* (2009):** Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis., 9(3):185-196.
25. **Huang N, Morlock L, Lee CH *et al.* (2005):** Antibiotic prescribing for children with nasopharyngitis (common colds), upper respiratory infections, and bronchitis who have health-professional parents. Pediatrics, 116(4): 826-32.
26. **Rasmussen ZA, Bari A, Qazi S *et al.* (2005):** Randomized controlled trial of standard versus double dose cotrimoxazole for childhood pneumonia in Pakistan. Bull World Health Organ., 83(1): 10-9.
27. **CSDH (2008):** Closing the gap in a generation: health equity through action on the social determinants of health. Final report of the Commission on Social Determinants of Health. Geneva: World Health Organization. www.csdh_finalreport_2008.
28. **Crighton EJ, Elliott SJ, Moineddin R *et al.* (2007):** A spatial analysis of the determinants of pneumonia and influenza hospitalizations in Ontario (1992–2001). Soc Sci Med., (64):1636–50.
29. **Guyatt GH, Oxman AD, Kunz R *et al.* (2008):** Going from evidence to recommendations. BMJ., 336:1049–51.
30. **Smylie J, Adomako P (2009):** Indigenous children's health report. Available at: http:// www.stmichaelshospital.com/crich/indigenous_childrens_health_report.php.